ABSTRACT NUMBER: ESOC2026LB147 EFFECT OF TIME TO TREATMENT WITH INTRAVENOUS TENECTEPLASE ON CLINICAL OUTCOMES IN ACUTE ISCHEMIC STROKE: A SECONDARY ANALYSIS OF THE TRACE-III TRIAL
Shuangzhe Wu, Zhixin Cao, Liyuan Wang, Manjun Hao, Yunyun Xiong, Yongjun Wang · 2026
Read ABSTRACT NUMBER: ESOC2026LB147 EFFECT OF TIME TO TREATMENT WITH INTRAVENOUS TENECTEPLASE ON CLINICAL OUTCOMES IN ACUTE ISCHEMIC STROKE: A SECONDARY ANALYSIS OF THE TRACE-III TRIAL by Shuangzhe Wu, Zhixin Cao, Liyuan Wang, Manjun Hao, Yunyun Xiong, Yongjun Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13144968.txt.
Description
Shuangzhe Wu and co-authors ask whether treatment timing changes the benefit of a clot-busting drug in stroke, in a 2026 conference abstract. The drug, tenecteplase, was trialled in patients treated between four and a half and twenty-four hours after the stroke was last known to be absent. This follow-up analysis splits five hundred and sixteen patients by time band and treats delay as a sliding scale.
In every time band, excellent recovery at ninety days was more common with the drug than with standard care, though none of the gaps reached statistical firmness. Each extra hour of delay showed no link with recovery or with bleeding in the brain, in either group. Death rates, oddly, trended lower with longer delays. No interaction between timing and treatment was found. The authors say the results support using the drug across the window, and hint it might extend further.
Catalog record
| CREATOR | Shuangzhe Wu, Zhixin Cao, Liyuan Wang, Manjun Hao, Yunyun Xiong, Yongjun Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |